HER 2/neu expression and gene amplification in colon cancer

Daniel R. Nathanson, Alfred T. Culliford IV, Jinru Shia, Beiyun Chen, Matthew D'Alessio, Zhao Shi Zeng, Garrett M. Nash, William Gerald, Francis Barany, Philip B. Paty

Research output: Contribution to journalArticle

78 Citations (Scopus)

Abstract

HER 2/neu is an important oncogene in breast cancer, but the prevalence and significance of HER 2/neu gene amplification in colon cancer have been poorly documented. We have evaluated HER 2/neu gene amplification and protein overexpression in a series of colon cancers to assess the frequency, concordance and clinical significance of these events. HER 2/neu gene copy number was measured in 154 primary colon tumors, 15 liver metastases and matched normal tissues using a quantitative PCR/ligase detection reaction (LDR) technique developed and validated in our laboratory. HER 2/neu copy number was confirmed by fluorescent in situ hybridization (FISH) in all tumors found to have gene amplification. In an independent and blinded fashion, HER 2/neu expression was assessed in paraffin sections from 139 of the tumor specimens using the HercepTest kit. HER 2/neu gene amplification was observed in 4 (2.4%) of the 169 tumor specimens and in none of the normal tissues. There was no apparent association with stage of disease, tumor grade or patient survival. Among 139 cases evaluated by immunohistochemistry (IHC), HER 2/neu overexpression was seen in 5 cases (3.6%). There was extremely high concordance (kappa = 0.852) between gene amplification and protein overexpression. The low prevalence of HER 2/neu gene amplification and protein overexpression suggests that this oncogene plays an infrequent role in the development and progression of colon cancer. These data indicate that the primary mechanism of dysregulated HER 2/neu expression in colon cancer, as in breast cancer, is gene amplification.

Original languageEnglish (US)
Pages (from-to)796-802
Number of pages7
JournalInternational Journal of Cancer
Volume105
Issue number6
DOIs
StatePublished - Jul 20 2003
Externally publishedYes

Fingerprint

erbB-2 Genes
Gene Amplification
Colonic Neoplasms
Neoplasms
Oncogenes
Breast Neoplasms
Proteins
Gene Dosage
Neoplasm Genes
Ligases
Fluorescence In Situ Hybridization
Paraffin
Colon
Immunohistochemistry
Neoplasm Metastasis

Keywords

  • Gene quantification
  • LDR
  • PCR

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Nathanson, D. R., Culliford IV, A. T., Shia, J., Chen, B., D'Alessio, M., Zeng, Z. S., ... Paty, P. B. (2003). HER 2/neu expression and gene amplification in colon cancer. International Journal of Cancer, 105(6), 796-802. https://doi.org/10.1002/ijc.11137

HER 2/neu expression and gene amplification in colon cancer. / Nathanson, Daniel R.; Culliford IV, Alfred T.; Shia, Jinru; Chen, Beiyun; D'Alessio, Matthew; Zeng, Zhao Shi; Nash, Garrett M.; Gerald, William; Barany, Francis; Paty, Philip B.

In: International Journal of Cancer, Vol. 105, No. 6, 20.07.2003, p. 796-802.

Research output: Contribution to journalArticle

Nathanson, DR, Culliford IV, AT, Shia, J, Chen, B, D'Alessio, M, Zeng, ZS, Nash, GM, Gerald, W, Barany, F & Paty, PB 2003, 'HER 2/neu expression and gene amplification in colon cancer', International Journal of Cancer, vol. 105, no. 6, pp. 796-802. https://doi.org/10.1002/ijc.11137
Nathanson DR, Culliford IV AT, Shia J, Chen B, D'Alessio M, Zeng ZS et al. HER 2/neu expression and gene amplification in colon cancer. International Journal of Cancer. 2003 Jul 20;105(6):796-802. https://doi.org/10.1002/ijc.11137
Nathanson, Daniel R. ; Culliford IV, Alfred T. ; Shia, Jinru ; Chen, Beiyun ; D'Alessio, Matthew ; Zeng, Zhao Shi ; Nash, Garrett M. ; Gerald, William ; Barany, Francis ; Paty, Philip B. / HER 2/neu expression and gene amplification in colon cancer. In: International Journal of Cancer. 2003 ; Vol. 105, No. 6. pp. 796-802.
@article{251609ab4fff40e6a5b2e9a87be8221c,
title = "HER 2/neu expression and gene amplification in colon cancer",
abstract = "HER 2/neu is an important oncogene in breast cancer, but the prevalence and significance of HER 2/neu gene amplification in colon cancer have been poorly documented. We have evaluated HER 2/neu gene amplification and protein overexpression in a series of colon cancers to assess the frequency, concordance and clinical significance of these events. HER 2/neu gene copy number was measured in 154 primary colon tumors, 15 liver metastases and matched normal tissues using a quantitative PCR/ligase detection reaction (LDR) technique developed and validated in our laboratory. HER 2/neu copy number was confirmed by fluorescent in situ hybridization (FISH) in all tumors found to have gene amplification. In an independent and blinded fashion, HER 2/neu expression was assessed in paraffin sections from 139 of the tumor specimens using the HercepTest kit. HER 2/neu gene amplification was observed in 4 (2.4{\%}) of the 169 tumor specimens and in none of the normal tissues. There was no apparent association with stage of disease, tumor grade or patient survival. Among 139 cases evaluated by immunohistochemistry (IHC), HER 2/neu overexpression was seen in 5 cases (3.6{\%}). There was extremely high concordance (kappa = 0.852) between gene amplification and protein overexpression. The low prevalence of HER 2/neu gene amplification and protein overexpression suggests that this oncogene plays an infrequent role in the development and progression of colon cancer. These data indicate that the primary mechanism of dysregulated HER 2/neu expression in colon cancer, as in breast cancer, is gene amplification.",
keywords = "Gene quantification, LDR, PCR",
author = "Nathanson, {Daniel R.} and {Culliford IV}, {Alfred T.} and Jinru Shia and Beiyun Chen and Matthew D'Alessio and Zeng, {Zhao Shi} and Nash, {Garrett M.} and William Gerald and Francis Barany and Paty, {Philip B.}",
year = "2003",
month = "7",
day = "20",
doi = "10.1002/ijc.11137",
language = "English (US)",
volume = "105",
pages = "796--802",
journal = "International Journal of Cancer",
issn = "0020-7136",
publisher = "Wiley-Liss Inc.",
number = "6",

}

TY - JOUR

T1 - HER 2/neu expression and gene amplification in colon cancer

AU - Nathanson, Daniel R.

AU - Culliford IV, Alfred T.

AU - Shia, Jinru

AU - Chen, Beiyun

AU - D'Alessio, Matthew

AU - Zeng, Zhao Shi

AU - Nash, Garrett M.

AU - Gerald, William

AU - Barany, Francis

AU - Paty, Philip B.

PY - 2003/7/20

Y1 - 2003/7/20

N2 - HER 2/neu is an important oncogene in breast cancer, but the prevalence and significance of HER 2/neu gene amplification in colon cancer have been poorly documented. We have evaluated HER 2/neu gene amplification and protein overexpression in a series of colon cancers to assess the frequency, concordance and clinical significance of these events. HER 2/neu gene copy number was measured in 154 primary colon tumors, 15 liver metastases and matched normal tissues using a quantitative PCR/ligase detection reaction (LDR) technique developed and validated in our laboratory. HER 2/neu copy number was confirmed by fluorescent in situ hybridization (FISH) in all tumors found to have gene amplification. In an independent and blinded fashion, HER 2/neu expression was assessed in paraffin sections from 139 of the tumor specimens using the HercepTest kit. HER 2/neu gene amplification was observed in 4 (2.4%) of the 169 tumor specimens and in none of the normal tissues. There was no apparent association with stage of disease, tumor grade or patient survival. Among 139 cases evaluated by immunohistochemistry (IHC), HER 2/neu overexpression was seen in 5 cases (3.6%). There was extremely high concordance (kappa = 0.852) between gene amplification and protein overexpression. The low prevalence of HER 2/neu gene amplification and protein overexpression suggests that this oncogene plays an infrequent role in the development and progression of colon cancer. These data indicate that the primary mechanism of dysregulated HER 2/neu expression in colon cancer, as in breast cancer, is gene amplification.

AB - HER 2/neu is an important oncogene in breast cancer, but the prevalence and significance of HER 2/neu gene amplification in colon cancer have been poorly documented. We have evaluated HER 2/neu gene amplification and protein overexpression in a series of colon cancers to assess the frequency, concordance and clinical significance of these events. HER 2/neu gene copy number was measured in 154 primary colon tumors, 15 liver metastases and matched normal tissues using a quantitative PCR/ligase detection reaction (LDR) technique developed and validated in our laboratory. HER 2/neu copy number was confirmed by fluorescent in situ hybridization (FISH) in all tumors found to have gene amplification. In an independent and blinded fashion, HER 2/neu expression was assessed in paraffin sections from 139 of the tumor specimens using the HercepTest kit. HER 2/neu gene amplification was observed in 4 (2.4%) of the 169 tumor specimens and in none of the normal tissues. There was no apparent association with stage of disease, tumor grade or patient survival. Among 139 cases evaluated by immunohistochemistry (IHC), HER 2/neu overexpression was seen in 5 cases (3.6%). There was extremely high concordance (kappa = 0.852) between gene amplification and protein overexpression. The low prevalence of HER 2/neu gene amplification and protein overexpression suggests that this oncogene plays an infrequent role in the development and progression of colon cancer. These data indicate that the primary mechanism of dysregulated HER 2/neu expression in colon cancer, as in breast cancer, is gene amplification.

KW - Gene quantification

KW - LDR

KW - PCR

UR - http://www.scopus.com/inward/record.url?scp=0037495051&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0037495051&partnerID=8YFLogxK

U2 - 10.1002/ijc.11137

DO - 10.1002/ijc.11137

M3 - Article

VL - 105

SP - 796

EP - 802

JO - International Journal of Cancer

JF - International Journal of Cancer

SN - 0020-7136

IS - 6

ER -